ライフサイエンスコーパス: second generation

1 d its impact on clinical progression using a second-generation 18-kDa translocator protein positron e

2 A total of 421 patients underwent second-generation 28-mm cryoballoon-based PVI in 2 cente

3 hmia recurrences despite previous successful second-generation 28-mm cryoballoon-based PVI were inclu

4 STOP second generation (2G)-tyrosine kinase inhibitor (TKI) i

5 In that study, the authors used a second generation 4-1BB costimulatory-molecule-based chi

6 Here, we used second-generation 8-color multiparameter-flow cytometry

7 Second-generation ABL1 kinase inhibitors induce more pot

8 ith RP, during which 6 from 9 members of the second generation affected the disease.

9 The second-generation agent, dolutegravir (DTG), has enjoyed

10 Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to l

11 ajor resistance mechanism to both first- and second-generation ALK inhibitors.

12 stant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in

13 Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alec

14 ible path for structure-based development of second-generation ALLINIs.

15 legislative ban on mephedrone, a number of 'second-generation' analogs have appeared in the street d

16 A series of second-generation analogues for 2-(1-(2-(4-butylphenyl)-

17 Current efforts in developing second-generation and new rapid point-of-care diagnostic

18 Enzalutamide is a potent second-generation androgen receptor (AR) antagonist with

19 d safety of idelalisib in combination with a second-generation anti-CD20 antibody, ofatumumab, in a s

20 oop-derived antibodies, as well as optimized second-generation antibodies, demonstrated similar modes

21 Serum ACPA was measured using second-generation anticyclic citrullinated peptide enzym

22 Observational evidence showed that second-generation antidepressant use during pregnancy ma

23 ly significant difference in the efficacy of second-generation antidepressants (SGAs) versus most oth

24 , double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood s

25 Adjunctive second-generation antidepressants are associated with re

26 bo-controlled trials of first-generation and second-generation antidepressants for acute treatment of

27 t for trials on the efficacy of FDA-approved second-generation antidepressants for anxiety disorders.

28 and clinicians may prefer options other than second-generation antidepressants for the treatment of m

29 Adjunctive therapy with second-generation antidepressants is widely used to trea

30 tween either cognitive behavioral therapy or second-generation antidepressants to treat patients with

31 comparative effectiveness of treatment with second-generation antidepressants versus nonpharmacologi

32 Second-generation antidepressants were associated with a

33 wort [Hypericum perforatum]), exercise, and second-generation antidepressants.

34 nd few data are available for the effects of second-generation antiepileptic drugs on hypopituitarism

35 The efficacy of second-generation antihistamines was evaluated on the da

36 therapies that could enhance traditional and second-generation antimitotic agents.

37 ering 12 weeks of prospective treatment with second-generation antipsychotic drugs.

38 Long-acting, injectable, second-generation antipsychotic medication has tremendou

39 on of randomized controlled treatment with a second-generation antipsychotic.

40 ed hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio,

41 Some second-generation antipsychotics (eg, clozapine, olanzap

42 Second-generation antipsychotics (SGAs) have increasingl

43 Pooled second-generation antipsychotics (SGAs) were associated

44 2014, 487 women were enrolled: 353 who used second-generation antipsychotics and 134 comparison wome

45 analyses of studies on patients treated with second-generation antipsychotics and first-generation an

46 m a safety study of the relationship between second-generation antipsychotics and type 2 diabetes (ou

47 Second-generation antipsychotics are used to treat a spe

48 major malformations among infants exposed to second-generation antipsychotics during pregnancy relati

49 nia as well as on response to treatment with second-generation antipsychotics in patients with schizo

50 esults suggest that it would be unlikely for second-generation antipsychotics to raise the risk of ma

51 Several second-generation antipsychotics were superior to halope

52 live births with first-trimester exposure to second-generation antipsychotics, three major malformati

53 superiority of clozapine compared with other second-generation antipsychotics.

54 ychotic intake in patients treated only with second-generation antipsychotics.

55 rther increased by both first-generation and second-generation antipsychotics.

56 enia, but we found little difference between second-generation antipsychotics.

57 cs, and pharmacodynamics of ISIS-APO(a)Rx, a second-generation antisense drug designed to reduce the

58 els following treatment with volanesorsen, a second-generation antisense drug targeting apoC-III, wer

59 ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis

60 Custirsen is a second-generation antisense oligonucleotide that inhibit

61 FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifi

62 Finally, this second generation approach for noninvasive fetal whole-g

63 A second-generation approach to the synthesis of hydromorp

64 xt of AR mutations that confer resistance to second-generation AR antagonists.

65 , even when patients are treated with potent second-generation AR-targeted therapies abiraterone and

66 One second generation ASO, Kynamro, was recently approved by

67 n this study, we report the development of a second-generation BET protein degrader, BETd-246, which

68 than one year after the introduction of this second generation beta-lactam antibiotic into clinical p

69 The synergies of crop choice (first versus second generation biofuel crops), infrastructure develop

70 One of the drawbacks during second-generation biofuel production from plant lignocel

71 Second generation biofuels based on cellulosic ethanol p

72 ts major obstacles to both the production of second-generation biofuels and the generation of valuabl

73 The derivation of second-generation biofuels from non-edible biomass is vi

74 , which are valuable characteristics for the second-generation biofuels industry.

75 ss (Panicum virgatum), a strategic plant for second-generation biofuels.

76 F-V600E inhibition, but responsive to both a second-generation BRAF inhibitor and a MEK inhibitor.

77 elihood of reversion and enhance safety in a second-generation Candid#1 vaccine.

78 elihood of reversion and enhance safety in a second-generation Candid#1 vaccine.IMPORTANCE The live-a

79 and P removal coupled to N2O generation in a second generation CANDO process, CANDO+P.

80 ells with a lentiviral construct harboring a second generation CAR targeting both wtEGFR and EGFRvIII

81 ely high doses of both CD28- and 4-1BB-based second-generation CAR T cells achieved tumor eradication

82 to that previously determined by the Grubbs second-generation carbene complex: Ru1 was found to prom

83 ion, T cell activation, and - in the case of second-generation CARs - costimulation to augment T cell

84 (DFT), the reactivity of the Hoveyda-Grubbs second-generation catalyst 2 with allylbenzene, and disc

85 is effectively catalyzed with Hoveyda-Grubbs second-generation catalyst affording corresponding alpha

86 , using only 2.5 mol % of the Hoveyda-Grubbs second-generation catalyst in both metathesis and transf

87 ABL001 and second-generation catalytic inhibitors have similar cell

88 4(+) and CD8(+) TCM subsets and expressing a second-generation CD19 CAR containing the CD28 and CD3ze

89 ids from the SB platform to stably express a second-generation CD19-specific CAR and selectively prop

90 n strategies, and support the development of second-generation cell therapeutic products.

91 zobactam and ceftazidime/avibactam are 2 new second-generation cephalosporin/beta-lactamase inhibitor

92 The costimulatory properties of second-generation chimeric antigen receptors (CARs) dete

93 ion or pharmacologic blockade with the novel second-generation CHK1 inhibitor prexasertib (LY2606368)

94 In this study, we report the development of second-generation cobalt- and maleimide-based liposomes

95 ern settings, asthma is more prevalent among second-generation compared to first-generation migrants.

96 associated with daily dosing of SMT022357, a second-generation compound in this drug series with impr

97 Budesonide is a high-potency, second-generation corticosteroid designed to minimize sy

98 tics of freezing time and balloon size using second generation cryoballoon are still unknown.

99 The second-generation cryoballoon ablation is associated wit

100 The rate of late PV reconnection after second-generation cryoballoon ablation is low (1.25 PVs/

101 factors affecting late PV reconnection after second-generation cryoballoon ablation.

102 sophagus during PV isolation (PVI) using the second-generation cryoballoon are not known.

103 The second-generation cryoballoon delivers effective pulmona

104 The second-generation cryoballoon has better cooling propert

105 aimed to assess the medium-term efficacy of second-generation cryoballoon in patients with persisten

106 The second-generation cryoballoon is effective in achieving

107 Our findings indicated that second-generation cryoballoon use is associated with fav

108 scheduled for pulmonary vein isolation using second-generation cryoballoon were enrolled in this stud

109 lmonary vein isolation was performed using a second-generation cryoballoon.

110 Twenty dogs underwent PVI using second-generation cryoballoon.

111 onths), after index ablation using the 28-mm second-generation cryoballoon.

112 revent PNP during cryoballoon ablation using second-generation cryoballoon.

113 acy of PN monitoring during procedures using second-generation cryoballoons.

114 The photogenerated intermediate of the second-generation DASA was photo-accumulated at low temp

115 First and second-generation DASAs share a common photoisomerizatio

116 While there exist many read simulators for second generation data, there is a very limited choice f

117 nogashira coupling into a methoxy-terminated second generation dendrimer with persistent globular sha

118 The second-generation dendrimers of siRNA can be effectively

119 zed, is critical to the development of their second-generation derivatives to improve drug potency to

120 significantly lower in patients treated with second-generation DES (odds ratio, 0.51; 95% confidence

121 nt thrombosis was attenuated with the use of second-generation DES (OR: 1.54 [95% CI: 0.96 to 2.47])

122 Patients receiving second-generation DES for the treatment SVG disease have

123 Implantation of BRS versus second-generation DES in chronic total occlusion was ass

124 was significantly attenuated with the use of second-generation DES, although the analysis may have be

125 P<0.001) were lower in patients treated with second-generation DES, but not with first-generation DES

126 address this question in patients receiving second-generation DES.

127 eived first-generation DES, and 47% received second-generation DES.

128 Among DES, second-generation devices have substantially improved lo

129 3 trials involving stent retrievers or other second-generation devices in a peer-reviewed publication

130 Endovascular thrombectomy with second-generation devices is beneficial for patients wit

131 s relative to input H2O2 concentrations, the second-generation dihydroxy hydroperoxy peroxy radical (

132 Second generation direct-acting antiviral agents have re

133 If second-generation direct-acting antivirals are not avail

134 To evaluate these claims, we used second generation DNA sequencing and capture methods as

135 A novel series of second generation DPP1 inhibitors free from aorta bindin

136 assess the safety and performance of a novel second-generation drug-eluting absorbable metal scaffold

137 ere is a paucity of contemporary data on the second-generation drug-eluting stent use within SVG, and

138 eated with BRS (Absorb; Abbott Vascular) and second-generation drug-eluting stents (DES) at 5 institu

139 previous analyses did not evaluate PCI with second-generation drug-eluting stents.

140 isk for myocardial infarction increases with second-generation drugs.

141 A second-generation dual-source CT system equipped with an

142 mography myocardial perfusion imaging with a second-generation dual-source scanner.

143 BP-DES) were developed to be as effective as second-generation durable-polymer drug-eluting stents (D

144 y less 12-month LLL than the implantation of second-generation EES.

145 Over the past decade, first and second generation EGFR inhibitors have significantly imp

146 Treatment of EGFR-driven tumor cells with second generation EGFR kinase inhibitors (EKIs), includi

147 ion, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials h

148 Although second generation endocrine therapies have significantly

149 a potential new additive for improvement of second-generation ethanol production.

150 a key step to achieve a viable production of second-generation ethanol.

151 omly assigned to biolimus-A9-eluting BP-DES, second-generation everolimus-eluting DP-DES, or thin-str

152 Second-generation everolimus-eluting stents (EES) have s

153 We describe a second-generation EWAS approach, which focuses on the po

154 reduced insulin secretion in first- (F1) and second-generation (F2) C57BL/6J male mice offspring.

155 This approach has led to a new, second-generation family of chiral oxazaborolidinium cat

156 of ferrocene cored polyamidiamine dendrimers second generation (Fc-PAMAM (G2)), after which electrode

157 selectively enhances reproductive success in second-generation females carrying embryos with overlapp

158 Second-generation FLT3 inhibitors such as crenolanib may

159 The activation of second-generation fluorinated oxazaborolidines by the st

160 g the power of genome editing may usher in a second-generation form of gene therapy for the beta-glob

161 recombinant factor VIII products other than second-generation full-length recombinant factor VIII, e

162 emained even after controlling for parental (second generation (G2)) socioeconomic status and BMI.

163 s genes, we have developed a high-complexity second-generation genome-scale CRISPR-Cas9 gRNA library

164 with total masses of 20-80 solar masses once second-generation ground-based gravitational-wave observ

165 oup significantly outperformed the benchmark second-generation Grubbs catalyst in the ethenolysis of

166 ocytosis found 4 weeks of treatment with the second-generation H1 -antihistamine rupatadine, compared

167 ctiveness, cost-effectiveness, and safety of second-generation H1 -antihistamines in treatment of pri

168 First- and second-generation healthy women of Mexican descent (n =

169 e addressed these obstacles by engineering a second-generation, high-affinity AXL decoy receptor with

170 Belatacept, a second-generation, higher avidity variant of CTLA4Ig (ab

171 Custirsen (OGX011) is a second generation highly specific antisense oligonucleot

172 However, the creation of second-generation, highly selective Aurora kinase inhibi

173 thesis-active Ru intermediates formed by the second-generation Hoveyda and Grubbs catalysts.

174 rties to be tuned, giving access to modified second-generation Hoveyda-Grubbs-type catalysts.

175 for their quadrivalent vaccine, is the first second-generation HPV VLP vaccine to be available on the

176 ation: HR, 0.90; 95% CI, 0.68-1.20; P = .49; second generation: HR, 1.19; 95% CI, 0.82-1.73; P = .36)

177 -wide RNA sequencing data confirmed that the second-generation HSP90 inhibitor onalespib altered the

178 compared the performance of three available second-generation human genome-wide CRISPR-KO libraries

179 GSK3532795 is a second-generation human immunodeficiency virus type 1 (H

180 From further computational work a second generation, in silico designed catalyst emerged,

181 subsequently applied to rationally design a second-generation inhibitor scaffold with a nearly optim

182 report important mechanistic advances and a second-generation inhibitor to provide insight into the

183 s, could serve as templates for synthesis of second generation inhibitors for further evaluation and

184 bitors and to the identification of refined, second generation inhibitors.

185 overcomes resistance to existing first- and second-generation inhibitors.

186 rved clinically, spurring the development of second-generation inhibitors.

187 es, which highlights a need for discovery of second-generation inhibitors.

188 a resistance profile similar to that of the second generation INST inhibitor (INSTI) dolutegravir.

189 ed the performance of the first (PQ-CSF) and second generation (IQ-CSF) RT-QuIC assays, and investiga

190 We found that treatment with the second-generation irreversible HER-family inhibitors, pa

191 Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inh

192 We have synthesized and evaluated first- and second-generation ITZ analogues for their anti-Hh and an

193 ors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.

194 and industrial sectors in the development of second-generation L1 VLP vaccines in terms of cost reduc

195 d provide insight for the rational design of second-generation, live-attenuated, recombinant JEV vacc

196 B and VEGFR2 in the 7-d first generation and second generation lungs.

197 sequencing methods provide longer reads than second generation methods and have distinct error charac

198 The transition from first- to second-generation MFC resulted in increased sensitivity

199 Using second-generation MFC, immune profiling concomitant to M

200 s of AD, and review recent studies using the second-generation mice.

201 he unique, non-Western context of Hong Kong, second-generation migrants had higher risk of hospitaliz

202 h provides means for rational development of second-generation MINIs.

203 cause additional phenotypes unrelated to AD Second-generation mouse models contain humanized sequenc

204 mutations will be intrinsically resistant to second-generation mTOR inhibitors.

205 have caused responses in 'N-of-1' cases, and second-generation mTOR kinase inhibitors (TORKi) are cur

206 re, we studied the effects of the first- and second-generation O-arylcarbamate-based FAAH inhibitors,

207 help of metabolite identification studies, a second generation of derivatives involving changes at th

208 The application of a second generation of genetics methods allows the dissect

209 With the goal of developing a second generation of HDAC inhibitors lacking this hydrox

210 This compound exemplifies a second generation of non-covalent NAAA inhibitors that m

211 progenitor cells capable of giving rise to a second generation of odontoblasts during reparative dent

212 d adversity, we argue that the field needs a second generation of research that recognizes multidirec

213 nsive efforts toward the identification of a second generation of S1P3-sparing S1P1 agonists.

214 We now present a second generation of UAS- and LexA-responsive CLIPf, SNA

215 In this study, we developed a second generation of vector systems for enhanced transcr

216 rtic valve replacement (TAVR) with first and second generations of transcatheter valves.

217 neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based

218 reprogram somatic cells to pluripotency, a "second generation" of cellular reprogramming involves li

219 ep mixing) are the progeny of a helium-rich 'second generation' of stars.

220 to adulthood and transmitted the reporter to second-generation offspring.

221 hagy than all previous datasets, producing a second-generation ontology of 220 functions.

222 From the second generation onward, the lineage bred endogamously

223 in optobiology, focusing on new features of second-generation optobiological tools.

224 sed after or were refractory to at least one second-generation or later TKI or were intolerant to sec

225 eneration or later TKI or were intolerant to second-generation or later TKIs and intolerant or refrac

226 e-activity studies led to the discovery of a second-generation ozonide, artefenomel (OZ439, 2), which

227 effects in collagen-induced arthritis of the second generation PAD inhibitor, BB-Cl-amidine.

228 iodegradable polymer DES generations against second-generation permanent polymer DES needs to be expl

229 Recently, second-generation PET radioligands that can reveal the e

230 the third-generation IMiD pomalidomide, the second-generation PIs carfilzomib and ixazomib, the DACI

231 Platelet-rich fibrin (PRF) is a second-generation platelet concentrate that releases var

232 Platelet-rich fibrin (PRF), a second-generation platelet concentrate, and atorvastatin

233 Herein, we show that first generation and second generation progeny from gestationally SS-exposed

234 Here we show that the second generation proteasome inhibitor ixazomib (MLN9708

235 fficacy and associated biologic effects of a second-generation proteasome inhibitor, ixazomib, in T-c

236 Other B-cell receptor inhibitors, second-generation proteasome inhibitors (eg, carfilzomib

237 highly effective drugs, including first- and second-generation proteasome inhibitors, immunomodulator

238 us familial hypercholesterolemia and over 35 second generation PS ASOs are at various stages of clini

239 haracterization, we find a recently designed second generation PTL, L-MAG0460, to have a favorable 2P

240 ion by optical wavefront shaping should make second generation PTL-controlled receptors suitable for

241 Optimization of a series of second-generation pyrrolidine-derived beta3-AR agonists

242 The authors used the second-generation radioligand [(11)C]PBR28 and PET to im

243 SPO), a biomarker of neuroinflammation, most second-generation radioligands are sensitive to the sing

244 Profiling of second-generation RAF inhibitors confirmed their improve

245 measurements of prion seeding activity with second-generation real-time quaking-induced conversion (

246 Necitumumab is a second-generation recombinant human immunoglobulin G1 EG

247 These results suggest that a second-generation recombinant vaccine can be rationally

248 Necitumumab is a second-generation, recombinant, human immunoglobulin G1

249 molecular composition show that the fate of second-generation RO2 radicals is key to understanding t

250 A series of second-generation ruthenium olefin metathesis catalysts

251 BI functionalized at its imide groups with a second generation self-assembling dendron is reported to

252 Generation Sequencing (TGS) long reads with Second Generation Sequencing (SGS) short reads, the accu

253 Second generation sequencing and high-density microarray

254 ata is difficult because datasets are large, second generation sequencing platforms have high error r

255 g Third Generation Sequencing long reads and Second Generation Sequencing short reads.

256 Second generation sequencing technologies are being incr

257 Second generation sequencing technologies paved the way

258 ctively address the read length issue of the second generation sequencing technology, but contain app

259 in order to attain bacterial diversity from second generation sequencing, Hill number can be a good

260 Second-generation sequencing technologies have been exte

261 ns with high copy numbers is challenging for second-generation sequencing, because the read length is

262 ming of new experimental techniques built on second-generation sequencing, which hold out the promise

263 from whole thymic and splenic tissues using second-generation sequencing.

264 vity relationships (SARs) leading to a novel second generation series of potent and selective reversi

265 rise to the development of a more efficient second-generation set of olefin cross-coupling condition

266 nzymatic inhibition was rendered by a potent second-generation small molecule inhibitor of ASPH.

267 the IOC clones good options for alternative second-generation smallpox vaccines.

268 t inhibition of SRC-3 and SRC-1 with SI-2, a second-generation SRC-3/SRC-1 small-molecule inhibitor,

269 stars are often suggested to be triggers of second-generation star formation.

270 ment of the cluster's central regions, where second-generation stars form.

271 ness due to variability in use of first- and second-generation stents, and off-protocol use of DAPT i

272 Rosuvastatin (RSV) is a new synthetic, second-generation, sulfur-containing, hydrophilic statin

273 A concise and scalable second generation synthesis of HIV maturation inhibitor

274 A second-generation synthesis of (-)-luminacin D based on

275 synthetic strategy, which also resulted in a second-generation synthesis of amphilectolide, confirms

276 The second-generation synthesis of hydromorphone was complet

277 We report a second-generation synthesis of the exceedingly potent an

278 An improved second-generation synthesis of the unnatural amino acid

279 vide a strategy for prognosis and therapy of second-generation TEVGs.

280 A series of high affinity second-generation thiazolopiperidine inhibitors of PI3Kg

281 on progeny cells was persistent through the second-generation time (~240min) until all of the progen

282 More patients receiving imatinib 800 mg or second-generation TKIs (ie, dasatinib or nilotinib) achi

283 Treatment with imatinib 800 mg or the second-generation TKIs dasatinib or nilotinib resulted i

284 assed in terms of molecular responses by the second-generation TKIs nilotinib, dasatinib, and bosutin

285 h imatinib 800 mg were similar to those with second-generation TKIs, although more patients discontin

286 A second-generation trabectedin analogue lurbinectedin (PM

287 (18)F-DPA-714 is a second-generation tracer for PET imaging of the 18-kDa t

288 (11)C-PBR28 is a second-generation translocator protein (TSPO) tracer wit

289 driven by numerous mechanisms and requiring second-generation treatment approaches.

290 The present study uses the novel second-generation TSPO PET radioligand [(18)F]FEPPA to e

291 Human PET imaging using the second-generation TSPO radiotracer [(11)C]DPA-713 reveal

292 Unfortunately, the application of these second-generation TSPO radiotracers has revealed additio

293 uating a subgroup of AD or MCI subject using second-generation TSPO tracers can be translated to the

294 However, the binding of second-generation TSPO tracers depends on the TSPO genot

295 It is a high-quality second-generation TSPO-binding PET radiotracer.

296 Efforts to develop second-generation vaccine candidates may concentrate on

297 Similar patterns were observed for the second-generation vaccine.

298 of administration (or both), development of second-generation vaccines, and the regional manufacture

299 n embryo viability was carried over into the second generation without further selection and was equa

300 ught to compare a hydrophilic polymer-based, second-generation zotarolimus-eluting stent (ZES) with a